Thousands of proteins are known to cause disease, but while the biological activity of these proteins is understood, the way to hit and modulate them with a drug is not. Nature still has ways to bind ...

In a recent study published in Virology, researchers pursued direct-acting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) drugs that compete for nucleotide-binding pockets (NBPs) of SARS ...

For years, a protein inside our cells has quietly powered billions of dollars' worth of cancer drugs. Now a team of ...

Scientists at Scripps Research have discovered a critical feature required by a promising new class of cancer drugs, known as CELMoDs, for them to be effective. CELMoDs are designed to attack cancer ...

Understanding how molecules interact is central to biology: from decoding how living organisms function to uncovering disease mechanisms and developing life-saving drugs. In recent years, models like ...

Some of the toughest challenges in treating disease are presented by “undruggable” proteins whose structures and roles in disease are known but are seemingly unable to be targeted by drugs that will ...

Some proteins shift their shape when exposed to different temperatures, revealing previously unknown binding sites for medications. The findings could revolutionize wide swathes of biology by ...

Misbehaving proteins are behind many diseases. One way drugmakers incapacitate these bad actors is to deploy molecules that bind to them. But finding solid footholds on the proteins to block their ...

Various approaches to such protein redesign have drawbacks. Traditional methods include time-consuming trial and error efforts, and many models in the emerging field ...

One challenge for protein engineers is to produce biopharmaceuticals that can withstand the proteolytic conditions of the gastrointestinal tract and serum. This was one of many challenges discussed at ...